Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease

Clinical Gastroenterology and Hepatology

Volumn 12, Issue 3, 2014, Pages

  Colombel, Jean Frédéric ^a   Sandborn, William J ^b   Allez, Matthieu ^c   Dupas, Jean Louis ^d   Dewit, Olivier ^e   D'Haens, Geert ^f   Bouhnik, Yoram ^g   Parker, Gerald ^h   Pierre Louis, Bosny ^h   Hébuterne, Xavier ^i,j  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAINT LOUIS HOSPITAL   (France)

^d AMIENS UNIVERSITY HOSPITAL   (France)

^e CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

^g BEAUJON HOSPITAL   (France)

^h UCB PHARMA   (Belgium)

ⁱ UNIVERSITY HOSPITAL OF NICE   (France)

^j UNIVERSITÉ CÔTE D'AZUR   (France)

more..

Author keywords

CDAI; MUSIC Trial; PK Study; TNF Inhibitor

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; MERCAPTOPURINE; METHOTREXATE;

ADULT; ADULT DISEASE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CROHN DISEASE; CROHN DISEASE ENDOSCOPIC INDEX OF SEVERITY; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LOADING DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OUTCOME ASSESSMENT; REMISSION; SUBCUTANEOUS IMMUNOTHERAPY; YOUNG ADULT;

CDAI; MUSIC TRIAL; PK STUDY; TNF INHIBITOR;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; COLONOSCOPY; CROHN DISEASE; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, SUBCUTANEOUS; MALE; PLASMA; POLYETHYLENE GLYCOLS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84893898345     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.10.025     Document Type: Article

References (29)

1. Baumgart D.C., Sandborn W.J. Crohn's disease. Lancet 2012, 380:1590-1605.
2. D'Haens G.R., Fedorak R., Lemann M., et al. Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease. Inflamm Bowel Dis 2009, 15:1599-1604.
3. Sandborn W.J., Feagan B.G., Hanauer S.B., et al. Areview of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002, 122:512-530.
4. D'Haens G. Anti-TNF-alpha treatment strategies: results andclinical perspectives. Gastroenterol Clin Biol 2009, 33:S209-S216.
5. Rutgeerts P., Vermeire S., Van A.G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?. Gut 2007, 56:453-455.
6. Cimzia (certolizumab pegol) (prescribing information) 2012, UCB, Inc, Smyrna, GA.
7. Sandborn W.J., Feagan B.G., Stoinov S., et al. Certolizumab pegol for the treatment of Crohn's disease. NEngl J Med 2007, 357:228-238.
8. Schreiber S., Khaliq-Kareemi M., Lawrance I.C., et al. Maintenance therapy with certolizumab pegol for Crohn's disease. NEngl J Med 2007, 357:239-250.
9. Hebuterne X., Lemann M., Bouhnik Y., et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut 2013, 62:201-208.
10. Mary J.Y., Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 1989, 30:983-989.
11. Colombel J.F., Feagan B.G., Sandborn W.J., et al. Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm Bowel Dis 2012, 18:349-358.
12. Ordas I., Feagan B.G., Sandborn W.J. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol 2012, 10:1079-1087.
13. Maser E.A., Villela R., Silverberg M.S., et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006, 4:1248-1254.
14. Lichtenstein G.R., Thomsen O.O., Schreiber S., et al. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months. Clin Gastroenterol Hepatol 2010, 8:600-609.
15. Sandborn W., Binion D., Rubin D., et al. Antibodies against certolizumab pegol (CZP), plasma concentrations of CZP and efficacy in patients with Crohn's disease receiving continuous CZP therapy with or without concomitant immunosuppressants. Am J Gastroenterol 2011, 106(Suppl 2):S439-S440. [abstr].
16. Sandborn W., Feagan B., Lee S., et al. Baseline C-reactive protein (CRP) and plasma anti-TNF concentration in patients with active Crohn's disease treated with certolizumab pegol (CZP). Am J Gastroenterol 2011, 106(Suppl 2):S454. [abstr].
17. Brandse J.F., Wildenberg M., de Bruyn J.R., et al. Fecal loss of infliximab as a cause of lack of response in severe inflammatory bowel disease. Gastroenterology 2013, 144(Suppl 1). s-36.
18. Karmiris K., Paintaud G., Noman M., et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009, 137:1628-1640.
19. Jones J., Loftus E.V., Panaccione R., et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol 2008, 6:1218-1224.
20. Solem C.A., Loftus E.V., Tremaine W.J., et al. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005, 11:707-712.
21. Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993, 259:87-91.
22. Inadera H. The usefulness of circulating adipokine levels for the assessment of obesity-related health problems. Int J Med Sci 2008, 5:248-262.
23. Kershaw E.E., Flier J.S. Adipose tissue as an endocrine organ. JClin Endocrinol Metab 2004, 89:2548-2556.
24. Dandona P., Weinstock R., Thusu K., et al. Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss. JClin Endocrinol Metab 1998, 83:2907-2910.
25. Gandhi A., Moorthy B., Ghose R. Drug disposition in pathophysiological conditions. Curr Drug Metab 2012, 13:1327-1344.
26. Bhalme M., Sharma A., Keld R., et al. Does weight-adjusted anti-tumour necrosis factor treatment favour obese patients with Crohn's disease?. Eur J Gastroenterol Hepatol 2013, 25:543-549.
27. Bultman E., de Haar C., van Liere-Baron A., et al. Predictors of dose escalation of adalimumab in a prospective cohort of Crohn's disease patients. Aliment Pharmacol Ther 2012, 35:335-341.
28. Gremese E., Carletto A., Padovan M., et al. Obesity and reduction of the response rate to anti-tumor necrosis factor alpha in rheumatoid arthritis: an approach to a personalized medicine. Arthritis Care Res (Hoboken) 2013, 65:94-100.
29. Klaasen R., Herenius M.M., Wijbrandts C.A., et al. Treatment-specific changes in circulating adipocytokines: a comparison between tumour necrosis factor blockade and glucocorticoid treatment for rheumatoid arthritis. Ann Rheum Dis 2012, 71:1510-1516.